Its partner AtheroGenics Inc <AGIX> hopes to present results from a pivotal Phase III clinical trial to the American College of Cardiology (ACC) meeting in New Orleans in March and analysts noted the deadline for research submissions was Jan. 4.
Most (all?) conferences allow you to submit a placeholder if you think you will have news before the event. So I don't think the above logic holds. FWIW.
Market Data 
Markets 
AI
